News archives

Commences phase I clinical study of treatment for Parkinson's disease

20 January 2003

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the start of a phase I clinical study to evaluate the safety, tolerability and pharmacokinetic profile of its patented oral product, P63, which is under development as a treatment for neurodegenerative disorders, including Parkinson’s disease.

Preliminary results for the year ended 31 August 2002

5 December 2002

For the 2002 Preliminary Results

Successful completion of 28 day repeat dose clinical study of dementia treatment P58

3 October 2002

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”)

Future development of P57

30 July 2002

Phytopharm plc (”Phytopharm”) announces today that it has agreed with Pfizer Inc, (”Pfizer”) the future development programme for P57, Phytopharm’s novel appetite suppressant for the treatment of obesity and metabolic syndrome. The agreement follows the successful demonstration of proof of principle in man that was announced in December 2001.

Interim results for the period to 28 February 2002

9 May 2002

For the 2002 Interim Results

Dementia Treatment

22 April 2002

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the commencement of the final stage of a clinical study to evaluate the safety, tolerability, pharmacokinetic profile and effect on cognitive performance of its oral treatment P58. P58 is under development as a treatment for age-related cognitive dysfunction, which typically presents as memory loss and dementia, including Alzheimer’s disease.

Opens new manufacturing unit in South Africa

11 April 2002

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today that it has completed the installation of a new botanical supplies unit in South Africa to substantially expand the manufacturing capacity for its appetite suppressant P57 in support of the further development of the product.

Retirement of Director

5 April 2002

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces that Ms Jayne Allan stands down today from the Board of Directors (the “Board”) as Director of Resource and Planning to spend more time with her young family. Ms Allan has worked for the business for over 10 years and was appointed to the Board in October 1999.

Commences European multi-centre study of P7v in canine atopic dermatitis

29 March 2002

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the start of a European multi-centre study of P7v, its novel, patented botanical product for the treatment of canine atopic dermatitis (canine “eczema”).

Successful Completion of Proof of Principle Clinical Study of P57 for Obesity

5 December 2001

Phytopharm plc (PYM: London Stock Exchange) (”Phytopharm”) announces today the successful completion of the third and final stage of its proof of principle clinical study of P57. The objectives of this stage of the study included the evaluation of the safety, tolerability, pharmacokinetic profile and effect on calorie intake of P57. This is a patented product which is under development as an appetite suppressant for the treatment of obesity and related conditions.